Clinical Study
Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial
Table 2
Most common adverse events.
| Most common AEs | TTX | Placebo |
| Nausea | 68% (10% severe) | 23% (2% severe) | Dizziness | 61% (4% severe) | 18% (0% severe) | Oral hypoesthesia | 61% (0% severe) | 9% (0% severe) | Hypoesthesia | 48% (0% severe) | 10% (0% severe) | Oral paresthesia | 44% (0% severe) | 2% (0% severe) | Vomiting | 34% (3% severe) | 8% (0% severe) | Injection site irritation | 52% (6% severe) | 53% (7% severe) | Serious adverse events () | 6 patients | 3 patients | SAEs related to TTX (after unblinding) | 5 events from 3 subjects: ataxia (2), neurotoxicity (1), nystagmus (1), and aspiration pneumonia (1) | ā |
|
|
Statistical analyses of safety endpoints were descriptive only.
|